DaVita stock enters October 23 report after Q2 earnings beat
DaVita Inc. (DVA) surpassed Q2 2026 earnings expectations with an adjusted EPS of USD 4.02 and revenue up 5.2% to USD 3.55 billion. The company reaffirmed its full-year adjusted operating income and EPS guidance, despite facing headwinds from commercial mix changes. Analysts maintain a "Moderate Buy" consensus with a 12-month price target significantly above its current NYSE quote as the company approaches its Q3 earnings report on October 23, 2026.
DaVita stock after-hours at EUR 158.78: plus 0.19 percent versus prior close
DaVita Inc. stock traded after-hours at EUR 158.78 on October 5, 2026, marking a 0.19 percent increase from its prior close. The company also highlighted initiatives from its 2025 Community Care Report, including the DaVita Ladders program and Bridge to Your Dreams program for nursing students, along with significant investment in tuition reimbursement.
DaVita stock gained 1.33 percent on October 2
DaVita Inc. stock closed at USD 178.69 on October 2, 2026, gaining 1.33 percent, outpacing the S&P 500. The company reported Q2 2026 revenue of USD 3.554 billion and an adjusted EPS of USD 4.02, while analysts maintain a "Moderate Buy" consensus with an average target price of USD 233.43. This target is 30.64 percent above the current stock price, despite the stock remaining 27.80 percent below its 52-week high.
DaVita stock after-hours at EUR 158.48: plus 0.96 percent versus prior close
DaVita Inc. stock traded at EUR 158.48 in after-hours trading on October 2, 2026, marking a 0.96 percent increase compared to its prior close. This information was released by Rafael Müller, Editor-in-Chief. The stock's price on October 1, 2026, was EUR 156.98.
Wall Street Zen downgrades DaVita stock to Hold
Wall Street Zen downgraded DaVita (DVA) stock from Buy to Hold after the company reported mixed Q2 2026 results. Despite revenue rising 5.20% to $3.55 billion and diluted EPS beating consensus, the stock's performance and analyst caution contributed to the downgrade. DaVita reaffirmed its fiscal 2026 guidance, and the stock is trading at EUR 246.00, below its yearly high.
DaVita stock trades at EUR 154.65 as Q2 EPS beats estimates
DaVita Inc. (ISIN US23918K1088) saw its stock trade at EUR 154.65, up 0.14 percent, after reporting Q2 diluted EPS of USD 4.02, exceeding the USD 3.88 consensus. The company's revenue reached USD 3.554 billion, a 5.20 percent year-over-year increase, with an improved operating margin. Despite strong earnings, analyst sentiment remains cautious with a consensus "Hold" rating, though DaVita maintained its fiscal 2026 guidance for EPS, operating income, and free cash flow.
What Johns Hopkins Research Means for Kidney Transplant Access
Research from Johns Hopkins Medicine suggests that analyzing deceased donor urine for three protein biomarkers (uromodulin, osteopontin, and YKL-40) can significantly improve the prediction of long-term kidney transplant function when combined with the Kidney Donor Profile Index (KDPI). This method could lead to 20% fewer donor biopsies and approximately 700 more kidneys available for transplant annually from 10,000 deceased donors, by increasing confidence in using "marginal" kidneys. The study highlights a practical tool to expand the supply of transplantable kidneys and reduce the number of patients on dialysis.
Charter Communications, Inc. (CHTR) Stock Price, News, Quote & History
This article provides a comprehensive overview of Charter Communications, Inc. (CHTR) stock performance, financial data, and company information. It includes current stock price, historical data, analyst insights, earnings trends, and a business overview of the broadband connectivity company. The stock showed a closing price of 112.91 with an overnight price of 113.07, and significant year-to-date and 1-year returns.
DaVita HealthCare Partners Inc Stock Price Live, Charts & News
This article provides live stock price, charts, and news for DaVita HealthCare Partners Inc. (DVA), a company specializing in kidney dialysis services. It includes detailed financial data such as market capitalization, P/E ratio, balance sheets, income statements, and cash flow statements, along with historical stock performance. The article also lists recent US market news and popular US stocks.
Is DaVita Stock Underperforming the S&P 500?
DaVita Inc. (DVA) has underperformed the S&P 500 over the past three months, despite strong year-to-date and 52-week gains. The stock saw a significant drop after its Q2 earnings report due to investor focus on declining revenue per treatment, even though adjusted EPS rose. Analysts maintain a "Moderate Buy" rating with an expected upside.
Cigna Group (CI) Looks 58% Undervalued, Is The Recent Pullback A Buying Opportunity?
Cigna Group (CI) has seen a recent share price pullback, down 5% over the past month and 6% over three months, raising questions about whether this presents a buying opportunity. Despite being 55% below a fair value of $636 per share according to a valuation model, the article emphasizes that regulatory pressure, litigation, and cash conversion concerns warrant a meaningful discount to this figure. Investors are encouraged to review the full picture, including rewards and warning signs, before making investment decisions.
Form 4 DaVita HealthCare Partners For: 25 September By Investing.com
This article reports on a Form 4 filing for DaVita HealthCare Partners, dated September 25th. Form 4 filings are regulatory documents filed with the SEC when there's a change in the beneficial ownership of a company's securities by insiders. The article indicates this particular filing pertains to DaVita HealthCare Partners.
Form 4 DaVita HealthCare Partners For: 25 September By Investing.com
This article announces a Form 4 filing for DaVita HealthCare Partners on September 25. It is a brief, one-sentence news item from Investing.com UK. The article also provides real-time market data for various indices, commodities, and shares.
DaVita stock heads into the open after September 24 loss
DaVita stock experienced a 0.32 percent decline, closing at USD 183.14 on September 24, 2026, while the S&P 500 also fell by 0.02 percent to 7,704.13. The stock underperformed the S&P 500 by 0.30 percentage points. US trading is set to resume on September 25, 2026, amidst ongoing geopolitical uncertainties.
BrightSpring Health Services (BTSG) Short Interest & Short Float | Updated Sep 2026
As of September 15, 2026, BrightSpring Health Services (BTSG) had a short interest of 10.18 million shares, representing 5.30% of its public float, which is a 0.36% increase from the prior report. The short interest ratio is 4.6 days to cover, indicating it would take 4.6 days of average trading volume to cover all short positions. The article provides a historical table of short interest data and answers frequently asked questions about BTSG's short interest metrics and comparison to competitors.
DaVita Inc. stock underperforms Thursday when compared to competitors
DaVita Inc. (DVA) shares fell by 4.62% on Thursday, closing at $174.67, in a generally negative trading session for the stock market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. This marks the second consecutive day of losses for DaVita's stock.
NeoGenomics, Inc. (NEO) Stock forecasts
Argus has issued a report on NeoGenomics, Inc. (NEO), an oncology diagnostic testing and consultative services provider. The report was published on September 23, 2026. The current price of NEO stock is $19.56.
DaVita stock heads into the open after a 0.55 percent gain
DaVita Inc. stock closed on September 22, 2026, with a 0.55 percent gain at USD 183.34 on the NYSE, trading between USD 182.03 and USD 185.00. This close was significantly below its 52-week high but well above its 52-week low. The S&P 500, in contrast, experienced a 0.75 percent decline on September 23, 2026.
Fred Hutch buys former DaVita building in Federal Way for $18 million
Fred Hutch Cancer Center has acquired a former DaVita office building in Federal Way for $18 million. This purchase adds nearly 188,000 square feet to Fred Hutch's growing real estate portfolio. The acquisition was reported by Shawna De La Rosa of the Puget Sound Business Journal.
GE HealthCare taps retiring AT&T CFO for board of directors
GE HealthCare has announced the appointment of AT&T's outgoing chief financial officer, Pascal Desroches, to its board of directors, effective January 4, 2027. Desroches, who plans to retire from AT&T at the end of the year, brings extensive financial leadership experience from his roles at AT&T and WarnerMedia. His appointment comes as GE HealthCare considers divesting its patient care solutions business.
Is DaVita Stock Underperforming the S&P 500?
DaVita (DVA) stock has underperformed the S&P 500 over the past three months, despite strong longer-term gains and positive analyst expectations for future earnings. The recent dip followed its Q2 results, where investors focused on a decline in revenue per treatment. However, analysts maintain a "Moderate Buy" rating with significant upside potential.
Former Weyerhaeuser office building sells for $18M. Here’s who bought it
Fred Hutchinson Cancer Center has purchased a former Weyerhaeuser East Campus office building in Federal Way for $18 million. The building, previously owned by an LLC affiliated with Realty Income Corp., was once home to DaVita's Pacific Northwest corporate operations. Fred Hutch plans to announce its future plans for the 10.29-acre campus in 2027.
Is DaVita Stock Underperforming the S&P 500?
DaVita Inc. (DVA) has shown mixed performance compared to the S&P 500. While it has underperformed over the past three months, DaVita has significantly outperformed the index over the past year and year-to-date. Analysts generally hold a "Moderate Buy" rating for the stock, expecting strong bottom-line growth in the coming years.
DaVita stock holds above USD 183 as earnings estimates rise
DaVita Inc. (DVA) stock closed at USD 183.34, up 61.2% year-to-date, driven by strong Q2 EPS of USD 4.02 which beat estimates. Despite its significant rally, the stock maintains a lower P/E ratio compared to the broader market, and analysts hold a "Moderate Buy" consensus with an average price target of USD 233.43. The company's valuation remains supported by its earnings growth and increased revenue.
DaVita stock slips 0.65 percent ahead of the open
DaVita stock closed at USD 182.67 on September 21, 2026, marking a 0.65 percent decrease. The shares are 26.2 percent below their 52-week high but 80.9 percent above their 52-week low. The outlook for the next US trading session is provided in context of the S&P 500 and Nasdaq Composite performance.
GE Healthcare Technologies Inc. Announces Appointment of Pascal Desroches to Board of Directors, Effective January 4, 2027
GE HealthCare Technologies Inc. has announced the appointment of Pascal Desroches, the Senior Executive Vice President and CFO of AT&T, to its Board of Directors, effective January 4, 2027. Desroches brings over 30 years of leadership experience in finance, governance, and large-scale technology and digital transformation, having previously served as CFO of WarnerMedia and Turner Broadcasting. He is currently on the boards of Honeywell Aerospace and the Federal Reserve Bank of Dallas, and has prior healthcare governance experience with DaVita.
AT&T’s finance chief will join GE HealthCare’s board Jan. 4.
GE HealthCare has announced the appointment of Pascal Desroches, the current CFO of AT&T, to its Board of Directors, effective January 4, 2027. Desroches will bring over 30 years of experience in finance, governance, and technology transformation to the board. This appointment is expected to strengthen GE HealthCare's leadership as it pursues its strategy to advance precision care and innovation.
DaVita Inc. stock slips 0.65 percent as earnings support outlook
DaVita Inc. (DVA) stock closed down 0.65% at USD 182.67 on September 21, 2026, remaining significantly below its 52-week high but well above its low. Despite a "Moderate Buy" consensus rating and positive analyst outlook tied to strong Q2 results and earnings growth, the stock has not returned to its yearly peak. The average analyst target price is USD 233.43, indicating a potential upside of 27.1% from the September 18 closing price.
3 Surging Stocks That Don’t Need the AI Boom to Keep Winning
This article identifies three non-AI stocks—DaVita Inc. (DVA), Franklin Resources Inc. (BEN), and Archer Daniels Midland Co. (ADM)—that have demonstrated strong performance in 2026, returning over 30% YTD. These companies operate in sectors like healthcare, asset management, and agriculture, showing resilience and growth independent of the AI boom. The article suggests they could serve as diversification plays for investors concerned about an AI bubble or looking to balance their portfolios.
DaVita Inc. (DVA) Stock Analysis: Uncovering a 19.58% Upside Within the Healthcare Sector
DaVita Inc. (NYSE: DVA), a healthcare provider specializing in kidney dialysis, shows a potential upside of 19.58% according to analyst targets, with an average target price of $219.86. Despite mixed analyst sentiment and some cautionary technical indicators, its strong revenue growth, impressive EPS, and strategic positioning in value-based healthcare models suggest a compelling opportunity for long-term growth. The company's financial health is further supported by a forward P/E of 10.66 and over $1 billion in free cash flow.
Form DEF 14A CARDINAL HEALTH INC For: Nov 12
This DEF 14A filing from Cardinal Health Inc. outlines the company's proxy statement for its Annual Meeting of Shareholders on November 12, 2026. It details proposals including the election of 11 director nominees, an advisory vote on executive compensation, and the ratification of Ernst & Young LLP as the independent auditor for fiscal year 2027. The document also provides extensive information on corporate governance, director and executive compensation, and financial performance highlights for fiscal year 2026.
3 Surging Stocks That Don’t Need the AI Boom to Keep Winning
The article highlights three non-AI stocks—DaVita (DVA), Franklin Resources (BEN), and Archer Daniels Midland (ADM)—that have surged over 30% year-to-date in 2026. DaVita benefits from stable demand for dialysis, improved reimbursement rates, and cost discipline. Franklin Resources has seen moderated investor outflows and stronger-than-expected earnings, while Archer Daniels Midland's agricultural processing operations are profiting from global trends despite geopolitical volatility.
DaVita Slides as Recent Rally Cools Without an Obvious Fresh Catalyst
DaVita stock experienced a slide, cooling off after a recent rally. The decline occurred without any clear new catalysts to explain the change in its market performance. This suggests a natural pullback after a period of growth rather than a reaction to specific news.
Accendra Health Names Kenneth Gardner-Smith CEO, Adds Chief Commercial Officer
Accendra Health, Inc. (NYSE: ACH) has appointed Kenneth Gardner-Smith as its new president and CEO, effective early in the fourth quarter of 2026. Gardner-Smith, currently CEO of Veritas Veterinary Partners and a board member since 2022, will focus on higher-margin growth and operational efficiency for the home-based care company. Additionally, Scott Lloyd has been named Chief Commercial Officer, a new role to consolidate commercial strategy and strengthen growth accountability.
DaVita slides as recent rally cools without an obvious fresh catalyst
DaVita Inc. (DVA) saw its stock price drop by 5.6% due to apparent profit-taking after a recent strong rally. The decline occurred despite no clear negative company-specific news, with the stock having outperformed over the past month and benefiting from a recent analyst price target increase. Insider trading activity shows significant sales, particularly from Berkshire Hathaway Inc., while institutional investors show mixed activity with some adding and others reducing shares.
DaVita Inc. stock underperforms Thursday when compared to competitors
Shares of DaVita Inc. (DVA) fell by 5.56% on Thursday, closing at $183.09, despite an overall positive trading session for the broader market. The S&P 500 Index and Dow Jones Industrial Average both saw gains. This decline broke a four-day winning streak for DaVita's stock.
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
DaVita HealthCare (DVA) saw its stock price increase by 1.55% in a declining market, outperforming the S&P 500, Dow, and Nasdaq. The kidney dialysis provider's stock has risen 7.3% over the past month. Analysts expect significant year-over-year growth in both earnings and revenue for the upcoming report and the full year, with a Zacks Rank of #3 (Hold) and favorable valuation metrics compared to its industry.
What Is Putting Cigna Group (CI) Back In Focus?
Cigna Group (CI) is back in focus due to recent share price movements and its current valuation. The stock is considered 55% undervalued by Simply Wall St's model, with a fair value of $636 per share against a current price of $288.90. However, ongoing litigation and FTC monitoring could impact confidence in Cigna's valuation story.
A Look at DaVita Inc (DVA) After 4.3% Gain -- GF Value $195.67 v
DaVita Inc (DVA) saw its shares rise by 4.3% to $189.32, marking a significant year-to-date gain of 66.6%. While GuruFocus's GF Value™ indicates the stock is 3.2% undervalued at $195.67, a GF Score™ of 91/100 points to strong fundamentals, particularly in profitability and momentum, despite weak financial strength. Investors should exercise caution due to substantial insider selling and a mixed sentiment from institutional investors, even though the valuation suggests a potential buying opportunity.
DaVita Community Care Report 2025: Empowering Teammates Through Career Development and Education
DaVita's 2025 Community Care Report highlights its commitment to empowering teammates through career development and education, focusing on programs like DaVita Ladders and Bridge to Your Dreams (BTYD). These initiatives aim to create clear career pathways, enhance economic mobility, and build a skilled healthcare workforce. The report also details investments in leadership development, AI literacy, and comprehensive benefits to support employee well-being.
DaVita to pay $15M to settle data breach lawsuit
DaVita, a national kidney dialysis provider, has agreed to a $15 million settlement in a class action lawsuit stemming from a data breach in April 2025. The breach, carried out by the cybercriminal group Interlock, exposed sensitive client data including Social Security numbers and health insurance information. A Colorado judge has approved the agreement, with a final approval hearing expected next year.
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
DaVita Inc. (DVA) is recommended for retention due to strong execution in its Integrated Kidney Care (IKC) platform, improving treatment volumes, and investments in technology. The company posted solid first-quarter 2026 results and raised full-year guidance, with its stock outperforming industry and S&P 500 growth. However, competitive pressures, commercial payer-mix headwinds, and regulatory uncertainties remain key concerns.
Fresenius Logged Leaking Dialysis Bags as Property Damage and Waited Eight Months Before Recalling the Affected Lots
Federal regulators have issued a warning letter to Fresenius Medical Care AG and Co. KGaA, rebuking the company for waiting eight months to recall leaking peritoneal dialysis bags. The company initially classified the risk of peritonitis from these leaks as "property damage" rather than a severe health risk, despite its own risk matrix recommending the highest severity level for peritonitis. This delay exposed home dialysis patients to potentially non-sterile products, prompting regulators to demand immediate corrective actions and a comprehensive audit of the company's manufacturing facility.
Commitment to Helping Communities Thrive: DaVita Community Care Report 2025
DaVita released its 2025 Community Care Report, highlighting its extensive efforts to promote kidney health globally through various initiatives. The report details collaborations with organizations like the American Diabetes Association, the reimagined Community Health Experience for at-risk communities, and significant volunteer hours contributed by DaVita teammates. Additionally, it outlines the impact of the DaVita Giving Foundation and the Bridge of Life charity in supporting health education, scholarships, and healthcare improvements in underserved areas.
Commitment to Helping Communities Thrive: DaVita Community Care Report 2025
DaVita released its 2025 Community Care Report, detailing efforts to promote kidney health and support communities globally. Key initiatives include collaborating with the American Diabetes Association, launching the Community Health Experience for early detection, and significant teammate volunteerism. The report also highlights the DaVita Giving Foundation's support for playspaces, nursing scholarships, and medically tailored meals, alongside the international impact of Bridge of Life programs.
Why Is Encompass Health (EHC) Down 1.8% Since Last Earnings Report?
Encompass Health (EHC) shares have declined 1.8% since its last earnings report, underperforming the S&P 500 despite beating Q2 earnings estimates and raising its 2026 outlook. The company reported strong revenue growth driven by increased patient revenue per discharge and discharge volumes, though higher operating expenses partly offset these gains. EHC's financial position remains strong, with increased cash and assets, and management reaffirmed growth targets for 2023-2027.
Will Labcorp’s (LH) Digital Trial Upgrades and New Diagnostics Deal Subtly Shift Its Growth Narrative?
Labcorp (LH) recently announced upgrades to its Global Trial Connect platform, new hepatitis D testing, an FDA-cleared Alzheimer's blood test, and a renewed 10-year agreement with the U.S. Defense Health Agency. These strategic moves aim to reinforce Labcorp's position in advanced diagnostics and digitally-enabled clinical trials, potentially bolstering its growth narrative by improving customer stickiness and win rates. While these developments are supportive, investors still need to consider the importance of clinical trial volumes and ongoing reimbursement pressures.
News - DaVita to pay $15 million to settle data breach lawsuit affecting millions of dialysis patients
DaVita Inc., a major kidney dialysis provider, has agreed to a $15 million settlement for a class action lawsuit stemming from a 2025 ransomware attack. The breach exposed personal and health information of approximately 2.7 million individuals. The settlement covers legal fees, administration costs, and a $10 million fund for class members, who can claim up to $2,500 for documented losses.
DaVita Community Care Report 2025: Leading With Integrity and Accountability
DaVita has released its 2025 Community Care Report, highlighting its commitment to integrity, accountability, and ethical leadership. The report details the company's robust compliance program, extensive teammate training, and progress on its environmental, social, and governance (ESG) goals, including a human rights impact assessment. DaVita proudly announced that it met or exceeded 19 of its 23 ESG goals set for 2025, aligning with several UN Sustainable Development Goals.
DaVita agrees to pay $15M to settle claims from data breach
DaVita, a major U.S. dialysis provider, has agreed to a $15 million settlement for a class action lawsuit stemming from a data breach last year that affected approximately 2.7 million people. The breach was a ransomware attack carried out by the cybercriminal group Interlock, which cost DaVita $25 million in 2025 and led to the exposure of sensitive patient data, including Social Security numbers and health insurance information. The settlement aims to address the injuries sustained by plaintiffs, such as ongoing fraud and identity theft threats, with a final approval hearing expected next year.
